BioLizard has been listed as a Trends Gazelle
As a fast-growing company, BioLizard has been recognised as one of the companies to watch in 2025! This recognition is part of a joint initiative by Trends, Change the Game, and Kanaal Z, which closely monitors companies achieving the greatest growth based on value...
Single-cell vs. bulk sequencing: which one to use when?
Winner of the 2013 Nature’s method of the year: single-cell sequencing. It’s no surprise that this method has gained in popularity ever since. Before the award, bulk sequencing methods were the standard for analyzing the transcriptome and other omics. Throughout the...
AI in biotech: Fashioning the future of R&D and IP
In today’s dynamic biotech and biomedicine sectors, the transformative power of artificial intelligence (AI) stands at the forefront in R&D. To leverage AI to its full potential, it’s key to understand the nuanced, strategic advancements it brings –...
BioLizard joins Da’s Geniaal consortium
Ghent, October 24th, 2023. We are happy to announce that BioLizard has joined the Da’s Geniaal consortium. The Da’s Geniaal consortium aims to inspire youngsters between 10 and 14 years to take on more science and technology oriented studies, with a...